| Columbus Family Practice Associates, P.c. | |
|
4214 38 St Columbus NE 68601-1616 | |
| (402) 564-1338 | |
| (402) 564-8902 |
| Full Name | Columbus Family Practice Associates, P.c. |
|---|---|
| Speciality | Family Medicine |
| Location | 4214 38 St, Columbus, Nebraska |
| Authorized Official Name and Position | Kelsey Jareske (CREDENTIALER) |
| Authorized Official Contact | 4025641338 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Columbus Family Practice Associates, P.c. 4214 38 St. Columbus NE 68601-1616 Ph: (402) 564-1338 | Columbus Family Practice Associates, P.c. 4214 38 St Columbus NE 68601-1616 Ph: (402) 564-1338 |
| NPI Number | 1134236060 |
|---|---|
| Provider Enumeration Date | 08/24/2006 |
| Last Update Date | 11/08/2021 |
| Medicare PECOS PAC ID | 9234239922 |
|---|---|
| Medicare Enrollment ID | O20070710000946 |
News Archive
Six months after Republicans swept the midterm election by promising bold solutions to fiscal woes, they continue to struggle to find a unified voice on key issues and to overcome persistent divisions within the party.
Integra LifeSciences announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Vu aPOD™ Prime anterior lumbar interbody fusion (ALIF) device.
In a groundbreaking effort, 3,500 of the country's top high school students will build the world's largest wiki on melanoma research — and work toward finding that needle in a haystack to cure melanoma.
The fixed-ratio combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since September 2014 for adults with type 2 diabetes mellitus. It is given as an injection in addition to other blood-glucose lowering drugs when these alone or in combination with basal insulin are insufficient to lower blood glucose levels.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134236060 | NPI | - | NPPES |
| 2000 | Other | NE | BCBS OF NEBRASKA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
| Provider Name | Kay Marie Taylor |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1003240524 PECOS PAC ID: 3779555008 Enrollment ID: I20040809000247 |
News Archive
Six months after Republicans swept the midterm election by promising bold solutions to fiscal woes, they continue to struggle to find a unified voice on key issues and to overcome persistent divisions within the party.
Integra LifeSciences announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Vu aPOD™ Prime anterior lumbar interbody fusion (ALIF) device.
In a groundbreaking effort, 3,500 of the country's top high school students will build the world's largest wiki on melanoma research — and work toward finding that needle in a haystack to cure melanoma.
The fixed-ratio combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since September 2014 for adults with type 2 diabetes mellitus. It is given as an injection in addition to other blood-glucose lowering drugs when these alone or in combination with basal insulin are insufficient to lower blood glucose levels.
› Verified 7 days ago
| Provider Name | Dale A Zaruba |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1215907357 PECOS PAC ID: 9931137502 Enrollment ID: I20050803001149 |
News Archive
Six months after Republicans swept the midterm election by promising bold solutions to fiscal woes, they continue to struggle to find a unified voice on key issues and to overcome persistent divisions within the party.
Integra LifeSciences announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Vu aPOD™ Prime anterior lumbar interbody fusion (ALIF) device.
In a groundbreaking effort, 3,500 of the country's top high school students will build the world's largest wiki on melanoma research — and work toward finding that needle in a haystack to cure melanoma.
The fixed-ratio combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since September 2014 for adults with type 2 diabetes mellitus. It is given as an injection in addition to other blood-glucose lowering drugs when these alone or in combination with basal insulin are insufficient to lower blood glucose levels.
› Verified 7 days ago
| Provider Name | Mary E Sueper |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1316009004 PECOS PAC ID: 6305946096 Enrollment ID: I20070710000962 |
News Archive
Six months after Republicans swept the midterm election by promising bold solutions to fiscal woes, they continue to struggle to find a unified voice on key issues and to overcome persistent divisions within the party.
Integra LifeSciences announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Vu aPOD™ Prime anterior lumbar interbody fusion (ALIF) device.
In a groundbreaking effort, 3,500 of the country's top high school students will build the world's largest wiki on melanoma research — and work toward finding that needle in a haystack to cure melanoma.
The fixed-ratio combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since September 2014 for adults with type 2 diabetes mellitus. It is given as an injection in addition to other blood-glucose lowering drugs when these alone or in combination with basal insulin are insufficient to lower blood glucose levels.
› Verified 7 days ago
| Provider Name | Kipton L Anderson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1124098710 PECOS PAC ID: 4183725989 Enrollment ID: I20080528000678 |
News Archive
Six months after Republicans swept the midterm election by promising bold solutions to fiscal woes, they continue to struggle to find a unified voice on key issues and to overcome persistent divisions within the party.
Integra LifeSciences announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Vu aPOD™ Prime anterior lumbar interbody fusion (ALIF) device.
In a groundbreaking effort, 3,500 of the country's top high school students will build the world's largest wiki on melanoma research — and work toward finding that needle in a haystack to cure melanoma.
The fixed-ratio combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since September 2014 for adults with type 2 diabetes mellitus. It is given as an injection in addition to other blood-glucose lowering drugs when these alone or in combination with basal insulin are insufficient to lower blood glucose levels.
› Verified 7 days ago
| Provider Name | Joseph L Citta |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1992960801 PECOS PAC ID: 5193863454 Enrollment ID: I20091109000007 |
News Archive
Six months after Republicans swept the midterm election by promising bold solutions to fiscal woes, they continue to struggle to find a unified voice on key issues and to overcome persistent divisions within the party.
Integra LifeSciences announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Vu aPOD™ Prime anterior lumbar interbody fusion (ALIF) device.
In a groundbreaking effort, 3,500 of the country's top high school students will build the world's largest wiki on melanoma research — and work toward finding that needle in a haystack to cure melanoma.
The fixed-ratio combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since September 2014 for adults with type 2 diabetes mellitus. It is given as an injection in addition to other blood-glucose lowering drugs when these alone or in combination with basal insulin are insufficient to lower blood glucose levels.
› Verified 7 days ago
| Provider Name | Michelle L Sell |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1801097308 PECOS PAC ID: 7719016963 Enrollment ID: I20100526000283 |
News Archive
Six months after Republicans swept the midterm election by promising bold solutions to fiscal woes, they continue to struggle to find a unified voice on key issues and to overcome persistent divisions within the party.
Integra LifeSciences announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Vu aPOD™ Prime anterior lumbar interbody fusion (ALIF) device.
In a groundbreaking effort, 3,500 of the country's top high school students will build the world's largest wiki on melanoma research — and work toward finding that needle in a haystack to cure melanoma.
The fixed-ratio combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since September 2014 for adults with type 2 diabetes mellitus. It is given as an injection in addition to other blood-glucose lowering drugs when these alone or in combination with basal insulin are insufficient to lower blood glucose levels.
› Verified 7 days ago
| Provider Name | Megan M Faltys |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1487801494 PECOS PAC ID: 4587834866 Enrollment ID: I20110823001054 |
News Archive
Six months after Republicans swept the midterm election by promising bold solutions to fiscal woes, they continue to struggle to find a unified voice on key issues and to overcome persistent divisions within the party.
Integra LifeSciences announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Vu aPOD™ Prime anterior lumbar interbody fusion (ALIF) device.
In a groundbreaking effort, 3,500 of the country's top high school students will build the world's largest wiki on melanoma research — and work toward finding that needle in a haystack to cure melanoma.
The fixed-ratio combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since September 2014 for adults with type 2 diabetes mellitus. It is given as an injection in addition to other blood-glucose lowering drugs when these alone or in combination with basal insulin are insufficient to lower blood glucose levels.
› Verified 7 days ago
| Provider Name | Daniel J Rosenquist |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1235109810 PECOS PAC ID: 3173569514 Enrollment ID: I20120111000850 |
News Archive
Six months after Republicans swept the midterm election by promising bold solutions to fiscal woes, they continue to struggle to find a unified voice on key issues and to overcome persistent divisions within the party.
Integra LifeSciences announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Vu aPOD™ Prime anterior lumbar interbody fusion (ALIF) device.
In a groundbreaking effort, 3,500 of the country's top high school students will build the world's largest wiki on melanoma research — and work toward finding that needle in a haystack to cure melanoma.
The fixed-ratio combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since September 2014 for adults with type 2 diabetes mellitus. It is given as an injection in addition to other blood-glucose lowering drugs when these alone or in combination with basal insulin are insufficient to lower blood glucose levels.
› Verified 7 days ago
| Provider Name | Staci Lyn Stempek |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1235653775 PECOS PAC ID: 2163856444 Enrollment ID: I20191218003275 |
News Archive
Six months after Republicans swept the midterm election by promising bold solutions to fiscal woes, they continue to struggle to find a unified voice on key issues and to overcome persistent divisions within the party.
Integra LifeSciences announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Vu aPOD™ Prime anterior lumbar interbody fusion (ALIF) device.
In a groundbreaking effort, 3,500 of the country's top high school students will build the world's largest wiki on melanoma research — and work toward finding that needle in a haystack to cure melanoma.
The fixed-ratio combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since September 2014 for adults with type 2 diabetes mellitus. It is given as an injection in addition to other blood-glucose lowering drugs when these alone or in combination with basal insulin are insufficient to lower blood glucose levels.
› Verified 7 days ago
| Provider Name | Lindsey Ellyn Clarey |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1023626140 PECOS PAC ID: 7214342500 Enrollment ID: I20210218002127 |
News Archive
Six months after Republicans swept the midterm election by promising bold solutions to fiscal woes, they continue to struggle to find a unified voice on key issues and to overcome persistent divisions within the party.
Integra LifeSciences announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Vu aPOD™ Prime anterior lumbar interbody fusion (ALIF) device.
In a groundbreaking effort, 3,500 of the country's top high school students will build the world's largest wiki on melanoma research — and work toward finding that needle in a haystack to cure melanoma.
The fixed-ratio combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since September 2014 for adults with type 2 diabetes mellitus. It is given as an injection in addition to other blood-glucose lowering drugs when these alone or in combination with basal insulin are insufficient to lower blood glucose levels.
› Verified 7 days ago
| Provider Name | Katie Beller |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1154948248 PECOS PAC ID: 2567865868 Enrollment ID: I20210729002137 |
News Archive
Six months after Republicans swept the midterm election by promising bold solutions to fiscal woes, they continue to struggle to find a unified voice on key issues and to overcome persistent divisions within the party.
Integra LifeSciences announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Vu aPOD™ Prime anterior lumbar interbody fusion (ALIF) device.
In a groundbreaking effort, 3,500 of the country's top high school students will build the world's largest wiki on melanoma research — and work toward finding that needle in a haystack to cure melanoma.
The fixed-ratio combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since September 2014 for adults with type 2 diabetes mellitus. It is given as an injection in addition to other blood-glucose lowering drugs when these alone or in combination with basal insulin are insufficient to lower blood glucose levels.
› Verified 7 days ago
| Provider Name | Marie D Rodehorst |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1164912523 PECOS PAC ID: 2860743127 Enrollment ID: I20210730001795 |
News Archive
Six months after Republicans swept the midterm election by promising bold solutions to fiscal woes, they continue to struggle to find a unified voice on key issues and to overcome persistent divisions within the party.
Integra LifeSciences announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Vu aPOD™ Prime anterior lumbar interbody fusion (ALIF) device.
In a groundbreaking effort, 3,500 of the country's top high school students will build the world's largest wiki on melanoma research — and work toward finding that needle in a haystack to cure melanoma.
The fixed-ratio combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since September 2014 for adults with type 2 diabetes mellitus. It is given as an injection in addition to other blood-glucose lowering drugs when these alone or in combination with basal insulin are insufficient to lower blood glucose levels.
› Verified 7 days ago
| Provider Name | Lynette A Klug |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1457928632 PECOS PAC ID: 0345696126 Enrollment ID: I20231031001284 |
News Archive
Six months after Republicans swept the midterm election by promising bold solutions to fiscal woes, they continue to struggle to find a unified voice on key issues and to overcome persistent divisions within the party.
Integra LifeSciences announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Vu aPOD™ Prime anterior lumbar interbody fusion (ALIF) device.
In a groundbreaking effort, 3,500 of the country's top high school students will build the world's largest wiki on melanoma research — and work toward finding that needle in a haystack to cure melanoma.
The fixed-ratio combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since September 2014 for adults with type 2 diabetes mellitus. It is given as an injection in addition to other blood-glucose lowering drugs when these alone or in combination with basal insulin are insufficient to lower blood glucose levels.
› Verified 7 days ago
News Archive
Six months after Republicans swept the midterm election by promising bold solutions to fiscal woes, they continue to struggle to find a unified voice on key issues and to overcome persistent divisions within the party.
Integra LifeSciences announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Vu aPOD™ Prime anterior lumbar interbody fusion (ALIF) device.
In a groundbreaking effort, 3,500 of the country's top high school students will build the world's largest wiki on melanoma research — and work toward finding that needle in a haystack to cure melanoma.
The fixed-ratio combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since September 2014 for adults with type 2 diabetes mellitus. It is given as an injection in addition to other blood-glucose lowering drugs when these alone or in combination with basal insulin are insufficient to lower blood glucose levels.
› Verified 7 days ago
Dynamic Life Therapy And Wellness Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 3763 39th Ave, Suite 100, Columbus, NE 68601 Phone: 402-606-4492 Fax: 402-615-4168 | |
Good Neighbor Community Health Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4500 63rd St, Columbus, NE 68601 Phone: 402-562-7500 Fax: 402-563-0544 | |
Luebbe Veterinary Services Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3516 50th St, Columbus, NE 68601 Phone: 402-276-3156 | |
Columbus Medical Center, P.c. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1454 28th Ave, Columbus, NE 68601 Phone: 402-564-2816 Fax: 402-564-1312 | |
Family Health Care Of Columbus P.c. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2485 39th Ave, Columbus, NE 68601 Phone: 402-564-9575 Fax: 402-562-7472 | |
Good Neighbor Community Health Center Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 4321 41st Ave, Columbus, NE 68601 Phone: 402-562-8952 Fax: 402-564-0611 |